The European League Against Rheumatism (EULAR) 2012 Noteworthy Takeaways
![](/report_cover/5562/european_league_against_rheumatism_eular_2012_noteworthy_takeaways_en.gif)
Among all oral options for the treatment of Rheumatoid Arthritis (RA), JAK inhibitors are ready to reach the market but the debate will continue – whether targeting specific JAK-1, 2, &3 or a multipronged approach like JAK 1/2, 1/3 is better? JAK1 may be the most suitable target as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and specific association with the common gamma chain of the IL-2 receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. In addition, systematic review of the safety of protein kinase inhibitors in clinical trials in RA suggested that JAK inhibitors (despite change in lipid profile) may be … For more detail, please read our report, released on 12th June on EULAR 2012, titled “EULAR 2012: Noteworthy Takeaways”.
COMPANIES MENTIONED
All
All